Introduction {#sec1-1}
============

Neuroendocrine tumors (NET) are a heterogeneous group of tumors that can originate from all of the neuroendocrine cells in the body, mostly from the lung and gastrointestinal tract including stomach, pancreas, small and large intestine, rectum. They can occur at any age, although it is often seen over 50 years. The incidence of NET is higher in men than in women. Even though they usually exhibit indolent clinical course, they may become very aggressive and rapidly become metastatic. Since most of NET are not functional, they often cause no signs and symptoms, which makes early diagnosis difficult and decreases survival by reducing the chance of curative treatment (Yao et al., 2008). In addition to early diagnosis, streaming patients into appropriate prognostic groups is an important component of treatment. However, the absence of frequently accepted classifications limits its benefit on survival (Bilimoria et al., 2007).

There is insufficient information about the incidence and frequency of many NET subgroups, including those with unknown primaries. In addition, long-term follow-up and survival-related data are limited in NET patients. The survival and the factors affecting it in patients with NET in many countries have not been identified. This suggests that further studies on prognostic parameters are needed (Oh et al., 2012).

In this study, we evaluated the prognostic significance of the clinicopathologic parameters routinely used in daily practise and the treatments administrated to the NET patients that we followed in our center between 2000 and 2016.

Materials and Methods {#sec1-2}
=====================

Patients who were diagnosed with pathologically verified NET and treated and followed up at our clinic between 2000 and 2016 were included in the study. The data concerning patients' age, gender, complaint for hospital admission, smoking history, the presence of carcinoid syndrome, stage, location of the primary, the location and number of metastases, type of surgery and treatment applied were obtained from their medical files. Patients with incomplete data, missing data, or multiple primers were excluded from the study. A total of 85 patients (32 males and 53 females) were included in the study. The TNM staging of patients and grading (G) of the tumor were performed according to AJCC and 2010 WHO classification, respectively (Bosman, 2010); World Health Organization; International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: International Agency for Research on Cancer).

The study protocol was approved by the Corporate Ethics Committee and found to comply with ethical principles for epidemiological investigations.

SPSS 15.0 for Windows program was used for statistical analysis. Descriptive statistics were given as mean, standard deviation, minimum, maximum for numerical variables, number and percentage for categorical variables. The numerical variables in the independent two groups were analyzed by Student t test and Mann Whitney U test if normal distribution condition was provided and not met, respectively. The comparisons of ratios between groups were made with Chi Square Analysis. Monte Carlo simulation was applied when conditions were not met. The survival analyzes were performed with Kaplan Meier Analysis. Determinants for survival were examined by Cox Regression Analysis. In univariate analysis, forward stepwise model was used for values with p\<0.100. The cut-off values were determined by using Roc Curve Analysis. The statistical significance level of alpha was accepted as p \<0.05.

Results {#sec1-3}
=======

A total of 85 patients, 32 (37.6%) male and 53 (62.4%) female, were included in the study. The median age was 55.7 (27-83) years. Eighty percent of the tumors were of gastroenteropancreatic system, most commonly stomach (27.1%) origin.

According to WHO classification, well differentiated NET (G1), moderately differentiated NET (G2) and neuroendocrine carcinoma (NEC)(G3) were detected in 53 (62.1%), 6 (7.1%), 26 (30.8%) patients, respectively. According to the AJCC / UICC staging, 31 (36.5%) patients had stage 1; 6 (7.1%) patients had stage 2; 11 (12.9%) patients had stage 3; 37 (43.5%) patients had stage 4 disease. Of the 59 (69.4%) patients, 54 (63.5%) and 5 (5.9%) underwent curative and palliative surgery, respectively. The lymph node metastasis was detected in 18 (30.5%) patients. At the time of diagnosis, 44.8% of patients had distant metastases ([Table 1](#T1){ref-type="table"}).

###### 

Demographic Data, Applied Treatments and Response Rates

                                           Mean±SD     Min-Max
  ----------------------- ---------------- ----------- ---------
  Age                                      55.7±14.4   27-83
  Ki-67 ratio (%)                          15.4±23.1   Jan-95
  Mitosis number                           3.8±9.6     0-50
  Number of metastases    0.87±1.12        0-3         
                                           n           \%
  Gender                  Male             32          37.6
  Female                  53               62.4        
  Smoking                                  30          35.3
  Symptom                 Abdominal pain   54          63.5
  GIS hemorage            8                9.4         
  Weight loss             5                5.9         
  Symptomatic             5                5.9         
  Hot flushes             3                3.5         
  Back pain               2                2.4         
  Shortness of breath     3                3.5         
  Swallowing difficulty   2                2.4         
  Jaundice                1                1.2         
  Palpable mass           1                1.2         
  Diarrhea                1                1.2         
  Carcinoid Syndrome      7                8.2         
  Grade                   G1               53          62.1
  G2                      6                7.1         
  G3                      26               30.8        
  Stage                   I                31          36.5
  II                      6                7.1         
  III                     11               12.9        
  IV                      37               43.5        
  Primary Localization    Stomach          23          27.1
  Pancreas                18               21.2        
  Small bowel             10               11.8        
  Appendix                10               11.8        
  Unknown primary         9                10.6        
  Lung                    8                9.4         
  Colorectal              7                8.2         
  Metastases              None             47          55.3
  Liver                   34               40          
  Lung                    2                2.4         
  Bone                    2                2.4         
  Lymph Node Metastases   No               41          69.5
  Yes                     18               30.5        
  Surgery Type            None             26          30.6
  Curative                54               63.5        
  Palliative              5                5.9         
  Octreotide                               25          36.8
  Octreotide response     PR               10          14.7
  SD                      13               19.1        
  PD                      2                2.9         
  Everolimus                               3           4.4
  Everolimus response     PR               1           1.5
  SD                      2                2.9         
  1\. line CT                              36          44.1
  1.line CT response      CR               6           8.8
  PR                      18               17.6        
  SD                      7                10.3        
  PD                      5                7.4         
  2\. line CT                              6           7.4
  2.line CT response      PR               4           5.9
  SD                      2                1.5         
  3\. line CT                              3           4.4
  3.line CT response      SD               2           2.9
  PD                      1                1.5         
  PRRT                                     2           2.9

G1, well differentiated; G2, moderately differentiated; G3, neuroendocrine carcinoma; CR, complete response; SD, Stable disease; PR, Partial response; PD, Progressive disease; PRRT: Peptide receptor radionuclide therapy

The somatostatin analogs to 25 (36.8%) patients, metastatic first-line cytotoxic chemotherapy (CT) to 36 (44.1%) patients, and second line CT to 6 (7.4%) patients were given as systemic treatment. 3 (3.5%) patients received everolimus. Two patients (2.3%) received peptide receptor radionuclide therapy (PRRT) ([Table 1](#T1){ref-type="table"}).

It was observed that the tumor grades varied with the localization of the tumors. Statistically significant differences were found in tumor grades of patients with primary lung (p=0.001), stomach (p=0.0001), and pancreas (p=0.022) compared to the others. G2 ratio of patients with primary lung, G3 ratio of patients with primary stomach and G1 ratio of patients with primary pancreas were significantly higher than the other primaries ([Table 3](#T3){ref-type="table"}).

###### 

Primary Tumor Localizations According to Grades

  Primary Localization       G1(n=53)      G2(n=6)   G3(n=26)                               
  -------------------------- ------------- --------- ------------ ------ ----------- ------ ----------
  Lung                       5             9.4       3            50     0           0      0.001
  Stomach                    7             13.2      0            0      16          61.8   0.001
  Pancreas                   16            30.2      1            16.7   1           3.8    0.022
  Small bowel                7             13.2      2            33.3   1           3.8    0.075
  Colorectal                 3             5.7       0            0      4           15.3   0.627
  Appendix                   10            18.9      0            0      0           0      0.164
  Unknown                    5             9.4       0            0      4           15.3   1
  Overall Survival (Years)   G1%(%)                  G2(%)               G1(%)              Total(%)
  5                          95.5                    91.1                19.1               75.2
  10                         95.5                    67.5                19.1               67.8
  15                         95.5                    67.5                19.1               60.3
  Stage (Years)              I+II (n=37)             III (n=11)          IV (n=37)          p
  5                          97.1                    88.3                57.4               0.001
  10                         93.3                    74.1                38.3               0.001
  15                         93.3                    0.55                38.3               0.001

G1, well differentiated; G2, moderately differentiated; G3, neuroendocrine carcinoma

###### 

Comparison of Characteristics of Patients with and without Exitus

                                   Last status          p                   
  ----------------------- -------- ------------- ------ ----------- ------- ---------
  Age                              63.4±12.2            52.9±14.3           0.007
  Ki-67 ratio (&)                  37.3±31.3            9.1±15.6            0.001
  Mitosis number                   18.3±22.9            1.5±1.5             0.031
  Metastases number                1.39±1.24            0.68±1.02           0.016
                                   n             \%     n           \%      p
  Gender                  Female   12            63.2   41          62.1    0.891
  Male                    7        36.8          25     37.9                
  Carcinoid Syndrome               0             0      7           10.6    0.341
  Smoking                          10            52.6   20          30.3    0.073
  Primary localization    Lung     0             0      8           12.1    0.315
  Stomach                 12       63.2          12     18.2        0.001   
  Pancreas                2        10.5          16     24.2        0.323   
  Small bowel             1        5.3           9      13.6        0.666   
  Colorectal              2        10.5          5      7.6         0.652   
  Appendix                1        5.3           9      13.6        1       
  Unknown                 1        5.3           7      10.6        0.666   
  Grade                   G1       4             21.1   49          74.4    \<0.001
  G2                      1        5.3           5      7.7                 
  G3                      14       73.7          12     17.9                
  Stage                   I        1             5.3    30          45.5    0.016
  II                      1        5.3           5      7.6                 
  III                     3        15.8          8      12.1                
  IV                      14       73.7          23     34.8                
  Metastases                       14            73.7   24          36.3    0.028
  Lymph Node Metastases            5             66.7   13          28      0.049
  Cerrahi Tipi            None     11            57.9   15          22.7    0.007
  Curative                5        26.3          49     74.2                
  Palliative              3        15.8          2      3                   
  Octreotie                        6             33.3   19          38      0.725
  Everolimus                       2             11.1   1           2       0.169
  1.line CT                        16            84.2   20          30.3    0.001
  2.line CT                        2             13.3   4           20      0.111
  3.line CT                        1             5.6    2           4       1

G1, well differentiated; G2, moderately differentiated; G3, neuroendocrine carcinoma; CT, chemotherapy

During follow-up, 19 (22.4%) patients died. 5-, 10-, and 15-year survival rates of all patients were 75.2%, 67.8%, and 60.3%, respectively; while median survival time was not reached. According to gradings, 5-,10- and 15-year survival rates were found as 95%, 95%, and 95% for G1; 91.1%, 67.5%, and 67.5% for G2; 19.1%, 19.1%, and 19.1% for G3; respectively; According to stages, 5-,10- and 15-year survival rates were found as 97.1%, 93.3%, and 93.3% for stage I+II; 88.3%, 74.1%, and 55.0% for stage III; 57.4%, 38.3%, and 38.3% for stage IV; respectively ([Table 2](#T2){ref-type="table"}).

Age (p=0.007), Ki-67 ratio (p=0.001), number of mitosis (p=0.031), number of metastases (p=0.016), the ratio of gastric localization of the primary tumor (p=0.001), presence of distant metastases (p=0.028), presence of lymph node metastases (p=0.049) and CT utilization rates (p=0.001) were statistically significantly higher in patients with exitus compared with those alive. In addition, the rates of G3 (p\<0.001) and stage IV disease (0.016) were significantly higher, whereas curative surgery rate was significantly lower (p=0.007) in patients who died ([Table 3](#T3){ref-type="table"}).

In univariate analysis; age (p\<0.001), stage (p=0.002), primary tumor localization (p=0.005), grade (p \<0.001), Ki-67 ratio (p\<0.001), the number of metastasis (p=0.001) and the type of surgery (p \<0.001) were found to be the factors affecting survival ([Table 4](#T4){ref-type="table"}). When factors affecting the OS were evaluated, age (p=0.024) and Ki-67 ratio (p\<0.001) were found to be the most significant factors according to Forward Stepwise analysis based on model consisted of variables of which p values were determined as \<0.100 in univariate analysis (age, smoking, primary tumor localization, grade, stage, metastasis, type of surgery, Ki-67 ratio) ([Table 5](#T5){ref-type="table"}).

###### 

Factors Affecting Survival in Univariate Analysis

  Variables                     Log rank p
  ----------------------------- ------------
  Gender                        0.791
  Age (\<65 vs ≥65)             \<0.001
  Carcinoid Syndrome presence   0.13
  Smoking                       0.085
  Stage                         0.002
  Grade                         \<0.001
  Ki-67 % (≤2. 2-20. \>20)      \<0.001
  Primary tumor localization    0.005
  Metastases number             0.001
  Curative surgery              \<0.001
  Lymph node metastases         0.986

###### 

Survival Determining Factors in Multivariate Analysis

                p         HR      %95 CI   
  ------------- --------- ------- -------- -------
  Age (Years)   0.024     1.067   1.009    1.128
  Ki67 %        \<0.001   1.048   1.024    1.073

There was a statistically significant difference in survival rates in the Ki-67 ratio groups (p\<0.001). Patients with a Ki-67 ratio of \>20% had a statistically significant lower survival rate than those with ≤2% (p\<0.001) and 3-20% (p=0.002). On the orher hand, no significant difference in survival rates was detected between patients with Ki-67 value of ≤2% and 3-20% (p=0.094) ([Figure 1](#F1){ref-type="fig"}). The median survival was 27±13.2 (95% CI:1.0-52.5) months in the Ki67 \>20% group, whereas median survival was not achieved in the other groups.

![Survival by Ki-67 Groups](APJCP-19-3597-g001){#F1}

According to the ROC analysis for the determination of mortality, the sensitivity and specificity of the Ki-67 ratio were found as 83.3% and 71.4% for the cut-off value of \>6% (AUC:0.813 (%95 CI: 0.664-0.963) ([Figure 2](#F2){ref-type="fig"}). The cumulative survival rate of patients with a Ki67 ratio of ≥6% was found to be statistically significantly lower than those with a Ki67 ratio of \<6% (p\<0.001) ([Figure 1](#F1){ref-type="fig"}). The median survival was not reached in the group with a Ki67 ratio of \<6% whereas it was 86±41.9 (95% CI:3.8-168.1) months in the group with a Ki67 ratio of ≥6%.

![Receiver Operating Characteristic Curve Analyses for the Determination of Mortality, the Sensitivity and Specificity of the Ki-67 Ratio were Found as 83.3% and 71.4% for the cut-off value of \>6% (AUC:0.813 (%95 CI: 0.664-0.963).](APJCP-19-3597-g002){#F2}

Discussion {#sec1-4}
==========

The naming and classification of NET have been changed several times, making it difficult to collect epidemiological information and compare studies published in the literature. The actual incidence of NETs is not known due to the lack of sufficient multicentric and epidemiological studies. This may explain the difference in incidence of NET between gender, race, country and continent (Hauso et al., 2008).

Over the last decade, attempts have been made to develop existing classification systems. There is limited data on long-term follow-up and survival in patients with NET. Because of infrequency and the differences in the diagnosis of NET, it is difficult to identify high risk factors. There are only a few studies that define prognostic factors, thus, factors affecting survival of patients with NET is lacking in many countries (Faggiano et al., 2012).

The median age of the patients at our study was 55.7 years, similar to other studies (Niederle et al., 2010; Araujo et al., 2013; Lewkowicz et al., 2015; Nikou et al., 2016). Five percent of the cases were asymptomatic. The incidence of carcinoid syndrome was 8.2%. Similar to other studies, the most common symptom was abdominal pain (Araujo et al., 2013; Lewkowicz et al., 2015). The most common disease grade seen in our study was G1. The most common localizations of the G1 disease were of the rectum and appendix in other studies, whereas it was of pancreas and appendix in our study (Niederle et al., 2010; Lewkowicz et al., 2015).

The pancreas and lung were the most common primary localizations in the study by Nikou et al., (2016). In another study, the most common primary localizations were alined as rectum, duodenum, pancreas and stomach while the most frequent stage, grade and metastatic site were stage 1, grade 1 and the liver, respectively (Lim et al., 2017). In our study, unlike other studies, the most common localizations were stomach, pancreas and small bowel (Garcia-Carbonero et al., 2010; Niederle et al., 2010; Lim et al., 2011; Lewkowicz et al., 2015). The most common distant metastasis site was liver.

Grade and Ki-67 ratio are required for pathologic classification and have prognostic significance. The Ki67 ratio was found to be \<2% in most of the studies (Garcia-Carbonero et al., 2010; Niederle et al., 2010; Lim et al., 2011; Araujo et al., 2013; Lewkowicz et al., 2015; Nikou et al., 2016; Lim et al., 2017). Likewise, in our study, the Ki67 rate was found to be ≤2% in 63.1%, 3-20% in 7.1%, and \>20% in 25% of patients.

The only curative treatment method in NET is the surgical resection. Surgery should be considered in patients with early stage, locoregional and resectable metastatic disease (Bilimoria et al., 2007). In our study, curative surgery was applied to 63.5% of patients and lymph node metastasis was detected in 30.5% of patients who underwent surgical treatment. Of our patients, 44.8% were metastatic at the time of diagnosis.

Somatostatin analogues in patients with NET provide symptom control, improve quality of life and control disease progression. Somatostatin analogues are a recommended treatment option for nonfunctional and functional G1/G2 NETs (Saglam et al., 2015). In our study, somatostatin analogues were given to 25 (36.8%) patients. Partial response in 10 (14.7%) patients, stable disease in 13 (19.1%) patients and progressive disease in 2 (2.9%) patients were observed. Due to tumor burden, the first line CT (platinum+etoposide) was given to 36 (44.1%) patients with metastatic disease. Of those, 6 (8.8%) patients had complete response, 18 (17.6%) patients had partial response and 7 (10.3%) patients had stable disease. In addition, 6 (7.4%) patients were given second line CT while PRRT was administered to 2 patients.

5-year overall survival rate varies between 67-90% in studies (Lim et al., 2011; Lewkowicz et al., 2015; Lim et al., 2017; Ma et al., 2017). In the study by Ma et al., (2017) the 5-year survival rate was 58.4% while survival rates in G1, G2 and G3 were 100%, 71.4% and 44.4%, respectively. In our study, 5-, 10-, and 15-year survival rates were 75.2%, 67.8%, and 60.3%, respectively. The 5-,10- and 15-year survival rates were estimated as 95%, 95%, and 95% for G1; 91.1%, 67.5%, 67.5% for G2; 19.1%, 19.1%, and 19.1% for G3; respectively. The decrease from 5- to 10-year survival rates of patients with G2 NET was remerkable which suggests that attention should be paid to the late recurrences after 5 years in G2 disease.

In a study that evaluated prognostic factors after resection of pancreatic NET, the presence of tumor necrosis, lymph node and liver metastasis was found to be associated with disease-free survival whereas age, tumor grade and the presence of distant metastasis were detected as the most significant determinants of survival (Bilimoria et al., 2008). Various studies have reported different survival rates according to tumor localization (Garcia-Carbonero et al., 2010; Lim et al., 2011; Lewkowicz et al., 2015). In the study by Lewkowicz et al., (2015) advanced stage, G2 and presence of metastasis at diagnosis were determined to be associated with poor prognosis in the univariate analysis, while presence of advanced stage and metastasis was found as the independent risk factors for poor outcome in the multivariate analysis. In another study, grade and stage were found as the independent risk factors for survival (Garcia-Carbonero et al., 2010). In the study by Ma et al., (2017) it was determined that 5-year survival rate of patients with advanced age, tumor localized in stomach, duodenum and colon, a tumor size of ≥4 cm and G3 disease was lower in univariate analysis. In multivariate analysis, age, stage, lymph node and distant metastasis were found to be independent risk factors affecting the prognosis of patients. In our study, age, Ki-67 and mitosis rate, stage, gastric localization, presence of distant metastases at the time of diagnosis, number of metastases, presence of lymph node metastasis and CT use were found to be factors affecting survival in univariate analysis. In multivariate analysis, age and Ki-67 ratio were found to be the most significant factors. The lower survival rates in gastric localization may be due to higher values of Ki-67 ratios of tumors in gastric localization. Furthermore, the use of CT in the treatment of symptomatic patients with high tumor burden may explain the lower survival rates in this group.

As a conclusion, in our study, age, Ki-67 ratio, number of mitosis, number of metastases, gastric localization of the primary tumor, presence of distant metastases, presence of lymph node metastases, G3 and stage IV disease and CT utilization rates were statistically significant higher in patients with exitus compared with those alive. The Ki-67 ratio and age were determined as the most important factors affecting survival. Ki-67 ratio has high sensitivity and specificity in predicting survival. We think that the Ki-67 ratio of ≥6% might be used to estimate survival.
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